Manolio Teri A
National Human Genome Research Institute, Building 31, Room 4B-09, 31 Center Drive, MSC 2154, Bethesda, MD 20892-2154, USA.
Pharmacogenomics. 2009 Feb;10(2):235-41. doi: 10.2217/14622416.10.2.235.
In the past 3 years, genome-wide association (GWA) studies have revolutionized the discovery of genetic variants associated with complex diseases. These studies present unique challenges in their conduct; particularly in the need for meticulous quality control of genotyping and for sample sizes large enough to withstand the severe penalty for multiple comparisons necessitated by testing hundreds of thousands of SNPs. They also present unique opportunities in the unprecedented detail with which they characterize an individual's genome and the potential for relating that information to any trait consistent with that person's informed consent. Such data exceed the abilities of any single group of investigators to mine them fully and by NIH policy are distributed to qualified investigators agreeing to specified terms of use. This report describes collaborative programs of the National Human Genome Research Institute's Office of Population Genomics for facilitating collection, analysis, interpretation, and dissemination of these data so that their research value can be maximized.
在过去三年中,全基因组关联(GWA)研究彻底改变了与复杂疾病相关的遗传变异的发现方式。这些研究在实施过程中面临着独特的挑战;特别是在基因分型的细致质量控制方面,以及在样本量方面,需要足够大以承受因测试数十万单核苷酸多态性(SNP)而产生的多重比较的严重惩罚。它们还提供了独特的机会,以前所未有的细节描绘个体的基因组,并有可能将这些信息与任何符合该人知情同意的性状联系起来。这样的数据超出了任何一组研究人员充分挖掘它们的能力,并且根据美国国立卫生研究院(NIH)的政策,这些数据会分发给同意特定使用条款的合格研究人员。本报告描述了国家人类基因组研究所群体基因组学办公室的合作项目,以促进这些数据的收集、分析、解释和传播,从而使它们的研究价值得以最大化。